Project Grant K99AI190129
Award Date
8/1/25
Completion Date
7/31/27
Dollars Obligated
$183K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Iowa City, IA 52242, USA
Similar Awards
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $648,924 to Iowa State University of Science and Technology to conduct research on the role of mosquito extracellular vesicles in malaria parasite killing and immune priming. The project aims to obtain a mechanistic understanding of how these extracellular vesicles function within the mosquito immune system...
This Project Grant award of $385,816 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research conducted by Iowa State University to identify key proteases involved in replicating the apicoplast genome of the malaria parasite Plasmodium falciparum. The primary goals are to: 1) confirm the localization of three candidate proteases within the apicoplast, assess their importance for parasite growth and maturation of the...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $738,445 Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) to Drexel University to develop an mRNA-based multivalent malaria vaccine. The project aims to optimize mRNA vaccine-induced antibody-mediated and cell-mediated immune responses targeting pre-erythrocytic and blood-stage malaria parasites. Specifically, the grant will support the design, production, and evaluation of mRNA vaccine candidates...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $813,160 to George Washington University to develop mRNA-LNP combination vaccines targeting multiple stages and species of the human malaria parasite. The grant aims to evaluate the protective efficacy of various vaccine antigens, including PFS25, PFS230, PFCSP, PVS25, and a chimeric PVCSP, both individually...
This federal Project Grant award of $708,202, provided by the National Institute of Allergy and Infectious Diseases (CFDA 93.855 Allergy and Infectious Diseases Research), supports research to identify targets of naturally acquired protection against severe Plasmodium falciparum malaria and develop them as novel blood-stage vaccine candidates. The award to Brown University will: 1) conduct a case-control study in Kenya to identify infants and children with severe malaria and matched controls, 2)...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $479,204 to the University of Maryland, Baltimore to conduct research on parasite variant surface antigens and their role in severe malaria. The research aims to identify parasite genes associated with severe disease, which could inform vaccine and drug development. Key aspects include: Sequencing variant surface antigen transcripts...
This Federal Project Grant award of $131,154 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) will support research by Yale University to quantify functional immune responses against Plasmodium falciparum, the parasite that causes malaria. The research objectives are to: 1) Assess mechanisms of protective blood-stage immune responses, including neutralization and opsonic phagocytosis, and 2) Understand how merozoite antigenic...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $690,500 to Boston University Medical Campus to investigate the mechanisms underlying poor immune responses to the booster dose of the RTS,S malaria vaccine in African children. The key objectives are to: 1) identify specific antibody responses and functions that are suboptimal after the booster dose; 2)...
This $423,500.00 Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research at the University of Utah to investigate the role of invariant natural killer T (iNKT) cells in shaping the immune response to Plasmodium infection, which can lead to the severe neurological condition of cerebral malaria. The research aims to define how the T cell receptor (TCR) signaling properties of different iNKT cell...
This federal Project Grant award of $429,000.00, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to examine chromatin architecture and gene regulatory networks in Anopheles coluzzii mosquito hemocyte cells. The key objectives are to 1) map chromatin architecture during immune activation in mosquito hemocyte cells, and 2) identify gene regulatory networks for the immune...